Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and period: The unaudited report covers the quarter and nine months ended June 30, 2015; the company’s fiscal year ends September 30. Citius is a development-stage pharmaceutical company focused on reformulating approved drugs. Suprenza, its marketed product, is licensed to Prenzamax for U.S. commercialization. Citius reported no revenue from operations during the periods presented.
Financial performance and position
| Metric | Three months ended June 30, 2015 | Nine months ended June 30, 2015 | Comparable 2014 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $773,729 | $2,261,548 | $1,305; $550,327 |
| Operating loss | $(773,729) | $(2,261,548) | $(1,305); $(550,327) |
| Net loss | $(824,972) | $(1,993,948) | $(34,880); $(659,573) |
| Net loss per share, basic and diluted | $(0.03) | $(0.06) | $(0.00); $(0.04) |
Comparable-period figures in the final column are for the three-month and nine-month periods, respectively. Gross margin and other operating margins are not meaningful because the company reported no revenue.
- Expenses: Nine-month research and development expense was $1,174,892, including $724,737 for development of a hemorrhoid-treatment product. General and administrative expense was $705,580; stock-based compensation was $381,076.
- Cash flow and liquidity: Cash and cash equivalents were $950,997 at June 30, 2015, down from $1,552,060 at September 30, 2014. Nine-month cash used in operating activities was $1,680,116; financing provided $1,079,053, resulting in a $601,063 net cash decrease. Working capital deficit was $1,185,873.
- Debt and liabilities: No promissory notes remained outstanding at June 30; $600,000 principal and $33,333 accrued interest had been converted into shares in December 2014. Current liabilities totaled $2,142,788, including a $1,716,847 derivative warrant liability. Total assets were $962,316 and stockholders’ deficit was $1,180,472.
- Capital and dilution: March–June 2015 private placements generated $1,164,500 gross proceeds; net cash proceeds were $1,079,053. The company had 33,226,211 shares outstanding at June 30 and reported 33,767,877 as of August 7, 2015.
Changes versus the prior comparable periods
- Nine-month operating expenses rose from $550,327 to $2,261,548, driven mainly by hemorrhoid-product development, higher corporate and consulting costs, and stock-based compensation. Nine-month net loss increased from $659,573 to $1,993,948.
- Quarterly net loss increased from $34,880 to $824,972, primarily reflecting higher operating expenses.
- For the nine months, a $272,147 gain from revaluing warrant liabilities and lower interest expense partly offset operating losses. The quarter included a $51,541 warrant revaluation loss.
- Cash declined by $601,063 over the nine-month period. The company converted debt to equity and raised additional equity capital.
Outlook, risks, and notable items
- Going concern: Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing operating cash outflows, working capital and stockholders’ deficits, no revenue, and limited capital. The company plans to raise additional funds, but success and acceptable terms are not assured.
- Management said available funds were expected to support operations for the next six months. In July 2015, after quarter-end, the company raised a further $292,500 gross through a unit sale.
- Suprenza’s license payments and development-cost reimbursements are contingent on Prenzamax achieving profitability; Citius had received neither profit-share payments nor development-cost reimbursement through June 30, 2015.
- Warrant liabilities are measured at fair value using models and significant management assumptions, including volatility; changes in valuation affect reported earnings. At June 30, the liability was $1,716,847.
- Disclosure controls and internal control over financial reporting were deemed ineffective. Reported material weaknesses included no independent board or audit committee, insufficient documented procedures, reliance on consultants for financial reporting, and inadequate segregation of duties.
- The filing identifies financing needs, clinical-trial success, regulatory approvals, commercialization, personnel, suppliers, and partners as risks. No legal proceedings were reported; management stated there were no changes to risk factors since its prior Form 10-K.
Important facts for investors to verify
- Whether the company can obtain enough financing to fund operations and clinical development, and the terms and dilution associated with any financing.
- Current cash runway and subsequent cash use compared with management’s six-month estimate.
- Clinical, regulatory, and development progress for the hemorrhoid-treatment product and any other pipeline programs.
- Whether Prenzamax achieves the contractual profitability conditions that could trigger payments to Citius for Suprenza.
- Warrant-liability valuation assumptions, potential share dilution, and the status of internal-control remediation.